Skip to content

Roberta Pacifici

11 papers in the library · 474 citations · publishing 2000-2021

Papers

Sort Most recent Most cited

Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users

Biology March 24, 2021 Nunzia La Maida, Esther Papaseit, Lucía Martínez de Soto et al. 14 citations

Synthetic cannabinoids (SCs) are one of the most frequent classes of new psychoactive substances monitored by the EU Early Warning System and World Health Organization. UR-144 is a SC with a relative low affinity for the CB1 receptor with respect to that for the CB2 receptor. As with other cannabinoid receptor agonists, it has been monitored by the EU Early Warning System since 2012 for severe...

DOI: 10.3390/biology10040257 (opens in new tab) Cannabis Heart rate Cannabinoid receptor Blood pressure +4

Magic truffles or Philosopher's stones: a legal way to sell psilocybin?

Drug Testing and Analysis August 9, 2012 Manuela Pellegrini, Maria Concetta Rotolo, Emilia Marchei et al. 21 citations

“Magic mushrooms” is the most common name given to hallucinogenic fungi containing the psychoactive alkaloids psilocybin and psilocin. In recent years, fungis' sclerotia, commonly called “magic truffles” have become a form of supply of psychoactive Psilocybe alkaloids since Psilocybe sclerotia are not specifically included in the laws banning the sale, the purchase and the use of such...

DOI: 10.1002/dta.1400 (opens in new tab) Psilocybin Chromatography Selected reaction monitoring Solid phase extraction +3

5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.

Addiction Biology January 2010 Rocío Martín‐Santos, Marta Torrens, Sandra Poudevida et al.

A 3-year longitudinal prospective study was conducted to compare the incidence of substance use disorders (SUD) and non-substance use disorders (NSUD) among ecstasy users and two control groups: one of cannabis users and the other of non-drug users. The 5-HTTLPR polymorphism related to NSUD was also studied. A total of 94 subjects were included: 37 ecstasy users, 23 cannabis users and 34...

Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study

Journal of Psychopharmacology January 21, 2008 Susana de Sola Llopis, Mónica Miguélez-Pan, Jordi Peña‐Casanova et al. 58 citations

There is important preclinical evidence of long lasting neurotoxic and selective effects of ecstasy MDMA on serotonin systems in non-human primates. In humans long-term recreational use of ecstasy has been mainly associated with learning and memory impairments. The aim of the present study was to investigate the neuropsychological profile associated with ecstasy use within recreational polydrug...

Combined immunomodulating properties of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis in humans

Addiction May 22, 2007 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 39 citations

ABSTRACT Aims Cell‐mediated immune function and the occurrence of mild infectious diseases was investigated. Participants Polydrug consumers of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis ( n = 37) compared to cannabis users only ( n = 23) and control group ( n = 34). Design A longitudinal prospective study with three cross‐sectional evaluations at time 0 and at 6 months and 1 year...

Disposition of Gamma-Hydroxybutyric Acid in Conventional and Nonconventional Biologic Fluids After Single Drug Administration: Issues in Methodology and Drug Monitoring

Therapeutic Drug Monitoring February 1, 2007 Sergio Abanades, Magı́ Farré, Mireia Segura et al. 66 citations

Little controlled drug administration data are available to aid in the interpretation of gamma-hydroxybutyric acid (GHB) distribution in conventional and nonconventional fluids and the potential correlation between the pharmacokinetics of GHB and drug effects. Single oral sodium GHB doses of 50 mg/kg were administered to five volunteers. Plasma, oral fluid, urine, and sweat were analyzed for...

DOI: 10.1097/ftd.0b013e3180307e5e (opens in new tab) Pharmacokinetics Pharmacology Sedative Oral administration +5

γ‐Hydroxybutyrate (GHB) in Humans

Annals of the New York Academy of Sciences August 1, 2006 Sergio Abanades, Magı́ Farré, Mireia Segura et al. 124 citations

Despite gamma-hydroxybutyrate (GHB) therapeutic uses and the increasing concern about its toxicity, few studies have addressed GHB dose-related effects under controlled administration and their relationship with its pharmacokinetics. The study design was double-blind, randomized, crossover, and controlled. As a pilot pharmacology phase I study, increasing doses of GHB were given. Single oral...

DOI: 10.1196/annals.1369.065 (opens in new tab) Gamma hydroxybutyrate Sedative Euphoriant Pharmacokinetics +4

Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Clinical Pharmacokinetics 2005 Mireia Segura, Magí Farré, Simona Pichini et al.

3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine derivative typically used for recreational purposes. The participation of cytochrome P450 (CYP) 2D6 in the oxidative metabolism of MDMA may suggest an increased risk of acute toxicity in CYP2D6 poor metabolisers. This study was aimed at assessing the contribution of CYP2D6 to MDMA disposition in vivo using paroxetine as a...

Cell‐Mediated Immune Response in MDMA Users After Repeated Dose Administration

Annals of the New York Academy of Sciences June 1, 2002 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 58 citations

A bstract : Acute administration of 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) produces time‐dependent immune dysfunction in humans. Recreational use of MDMA generally includes repeated drug consumption, often in association with other drugs, such as alcohol and cannabis. In the laboratory setting, repeated MDMA administration to healthy MDMA consumers produced a time‐dependent immune...

DOI: 10.1111/j.1749-6632.2002.tb04183.x (opens in new tab) MDMA Immune system Pharmacology Administration probate law +1

Sweat Testing of MDMA with the Drugwipe(R) Analytical Device: A Controlled Study with Two Volunteers

Journal of Analytical Toxicology March 1, 2001 Roberta Pacifici, Magı́ Farré, Simona Pichini et al. 50 citations

Rapid on-site tests for the analysis of drugs of abuse in unconventional specimens (e.g., sweat) have recently been developed. Two healthy volunteers familiar with the effects of methylenedioxymethamphetamine (MDMA) were given 100 mg of the drug as a single oral dose. MDMA and its main metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA) were determined in plasma and urine by gas...

Immunomodulating Activity of MDMA

Annals of the New York Academy of Sciences September 1, 2000 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 44 citations

Abstract MDMA (3,4‐methylenedioxymethamphetamine) use can cause neurochemical, behavioral and endocrine alterations, similar to those produced by exposure to acute stress, suggesting its potential as a “chemical stressor.” It is known that stressful stimuli can produce a depression of immune function and an alteration in immune cells distribution. In vitro exposure to MDMA resulted in a...

DOI: 10.1111/j.1749-6632.2000.tb05198.x (opens in new tab) MDMA Immune system Endocrinology Neurochemical +5